Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

• Status: Completed
• Trial end date: 2014-10-15

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving more than one chemotherapy drug (combination chemotherapy) together with cetuximab may kill more tumor cells.

PURPOSE: This randomized phase II trial is studying three different combination chemotherapy regimens to compare how well they work when given together with cetuximab in treating patients with metastatic esophageal cancer or gastroesophageal junction cancer.

• Phase: Phase 2

Details

• Lead Sponsor: Alliance for Clinical Trials in Oncology
• Collaborators: Bristol-Myers Squibb; Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Pfizer; Sanofi
• Treatments: Cetuximab; Cisplatin; Epirubicin; Fluorouracil; Irinotecan; Leucovorin; Oxaliplatin